Razuprotafib

• CAT Number: I008984
• CAS Number: 1008510-37-9
• Molecular Formula: C26H26N4O6S3
• Molecular Weight: 586.696
• Purity: ≥95%
• Synonyms: Razuprotafib;N-(4-{(2S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-phenylpropanamido}-2-[2-(thiophen-2-yl)-1,3-thiazol-4-yl]ethyl}phenyl)sulfamic acid
• Target: Protein Tyrosine Kinase/RTK
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: [4-[(2S)-2-[[(2S)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
• InChI: InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
• InChIKey: KWJDHELCGJFUHW-SFTDATJTSA-N
• SMILES: COC(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CC=C(C=C2)NS(=O)(=O)O)C3=CSC(=N3)C4=CC=CS4

Razuprotafib (CAT: I008984) is indeed a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP). By targeting and inhibiting VE-PTP, razuprotafib prevents the dephosphorylation of the endothelial cell (EC)-specific receptor tyrosine kinase (RTK) Tie2. This inhibition leads to the restoration of Tie2 activation, which is crucial for maintaining endothelial function and vascular stability. Upregulation of VE-PTP is observed in stressed endothelium associated with various diseases. By restoring Tie2 activation, razuprotafib has the potential to improve endothelial function, stabilize blood vessels, and mitigate vascular leakage and inflammation. This makes razuprotafib a promising candidate for therapeutic interventions in conditions where endothelial dysfunction is implicated.

Overview of Clinical Research

Originator: Procter & Gamble
Developer: Aerpio Pharmaceuticals; Akebia Therapeutics; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; Medical Technology Enterprise Consortium; New York University; Quantum Leap Healthcare Collaborative
Class: Amides; Antineoplastics; Carbamates; Eye disorder therapies; Small molecules; Sulfonic acids; Thiazoles; Thiophenes
Mechanism of Action: Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists
Orphan Drug Status: No
New Molecular Entity: Yes
Available For Licensing: Yes

Reference

[1] Int J Retina Vitreous. 2020 Oct 13;6:48. doi: 10.1186/s40942-020-00250-z. eCollection 2020.
The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye.
Nguyen QD(1), Heier JS(2), Do DV(1), Mirando AC(3), Pandey NB(3), Sheng H(3), Heah T(3).
DOI: 10.1186/s40942-020-00250-z PMCID: PMC7557096 PMID: 33072401